Granulocytic Expression of CD11b/CD18 and Thrombotic Risk in Patients with Myeloproliferative Neoplasms
References
- 1. Gamal TE, Mohamed G, Omina S, Mahmoud MK. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. Int J Clin Exp Pathol. 2015;8(9):11555-9.
- 2. Da Silva RR, Hatzlhofer BLD, Machado CGF, Lima ASM, Albuquerque DM, Santos MNN et al. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. Genet Test Mol Biomarkers. 2012;16(7):802-5.
- 3. Azevedo A, Silva SN, Reichert A, Lima F, Júnior E., Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. J. Biomedical Reports. 2017;7(4):370-6.
- 4. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015;1(1):97-105.
- 5. Levine RL. Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2009;22(4):489-94.
- 6. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676–82.
- 7. Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T et al. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pacific journal of cancer prevention: APJCP. 2016;17(10):4647-53.
- 8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweget JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
- 9. Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011;2(6):485-90.
- 10. Barbui T, Finazzi G, Falanga A; Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-84.
- 11. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.
- 12. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275-90.
- 13. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-51.
- 14. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchiolie R еt al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310-3.
- 15. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol. 2005;42(4):239-47.
- 16. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143-51.
- 17. Alvarez-Larrán A, García-Pagán JC, Abraldes JG, Arellano E, Reverter JC, Bosch J et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol. 2004;124(3):329-35.
- 18. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261-6.
DOI: https://doi.org/10.2478/jbcr-2021-0005 | Journal eISSN: 1313-9053
Language: English
Page range: 47 - 52
Submitted on: Sep 3, 2020
Accepted on: Apr 22, 2021
Published online: Jul 12, 2021
Published in print: Jun 1, 2021
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2021 Doroteya K. Todorieva-Todorova, Katya S. Kovacheva, Nikolay T. Tzvetkov, Svetla O. Blazheva, Tzvetan H. Lukanov, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.